BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 344 filers reported holding BIO-TECHNE CORP in Q3 2018. The put-call ratio across all filers is 1.17 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,050,000 | -18.7% | 14,623 | -19.6% | 0.00% | 0.0% |
Q1 2024 | $1,291,000 | -4.7% | 18,189 | +2.5% | 0.00% | 0.0% |
Q4 2023 | $1,354,000 | +5.0% | 17,738 | -6.0% | 0.00% | 0.0% |
Q3 2023 | $1,290,000 | -11.9% | 18,866 | +5.4% | 0.00% | -33.3% |
Q2 2023 | $1,465,000 | +16.9% | 17,901 | +4.7% | 0.00% | 0.0% |
Q1 2023 | $1,253,000 | -12.1% | 17,092 | -0.6% | 0.00% | 0.0% |
Q4 2022 | $1,426,000 | +20.9% | 17,197 | +315.1% | 0.00% | 0.0% |
Q3 2022 | $1,179,000 | -19.9% | 4,143 | -3.4% | 0.00% | -25.0% |
Q2 2022 | $1,471,000 | -21.8% | 4,287 | -1.3% | 0.00% | 0.0% |
Q1 2022 | $1,880,000 | -21.4% | 4,345 | -5.0% | 0.00% | -20.0% |
Q4 2021 | $2,393,000 | +12.9% | 4,575 | +3.4% | 0.01% | -16.7% |
Q3 2021 | $2,120,000 | +7.8% | 4,425 | -0.5% | 0.01% | 0.0% |
Q2 2021 | $1,967,000 | +27.9% | 4,446 | +10.5% | 0.01% | +20.0% |
Q1 2021 | $1,538,000 | +28.1% | 4,022 | +6.1% | 0.01% | 0.0% |
Q4 2020 | $1,201,000 | +34.2% | 3,791 | +2.8% | 0.01% | +25.0% |
Q3 2020 | $895,000 | -9.0% | 3,688 | -1.1% | 0.00% | -20.0% |
Q2 2020 | $984,000 | +52.1% | 3,730 | +8.8% | 0.01% | +25.0% |
Q1 2020 | $647,000 | -12.3% | 3,427 | +3.0% | 0.00% | 0.0% |
Q4 2019 | $738,000 | +10.6% | 3,326 | -2.0% | 0.00% | 0.0% |
Q3 2019 | $667,000 | +14.6% | 3,395 | +21.2% | 0.00% | +33.3% |
Q2 2019 | $582,000 | +12.4% | 2,801 | +6.8% | 0.00% | 0.0% |
Q1 2019 | $518,000 | +70.4% | 2,622 | +23.7% | 0.00% | +50.0% |
Q4 2018 | $304,000 | -15.6% | 2,120 | +18.2% | 0.00% | -33.3% |
Q3 2018 | $360,000 | +70.6% | 1,794 | +2.2% | 0.00% | +50.0% |
Q3 2017 | $211,000 | -40.2% | 1,755 | -52.6% | 0.00% | +100.0% |
Q1 2016 | $353,000 | +14.2% | 3,702 | +8.3% | 0.00% | -75.0% |
Q4 2015 | $309,000 | -47.5% | 3,418 | -46.4% | 0.00% | -55.6% |
Q4 2014 | $589,000 | – | 6,377 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |